Tumor
Conditions
Interventions
Hydrotropium ethanolamine tablets and/or thiotropium fegestatin group:None
Sponsors
The Second Affiliated Hospital of Zunyi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Prospective cases: patients signed an informed consent form to voluntarily enroll in the study; retrospective cases were exempted from signing the informed consent form; 2. Pathologically or cytologically confirmed diagnosis of non-myeloid malignant tumor; 3. Age = 18 years, receiving anti-tumor therapy (chemotherapy, radiotherapy, target-free therapy, etc.); 4. investigator assessment of the need for prophylaxis or treatment of hematological toxicity associated with the patient's oncological treatment;
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating females; 2. allergy to thiotepa fexofilgrastim, polyethylene glycol recombinant human granulocyte stimulating factor, TPO-RA, and other agents expressed against Escherichia coli; 3. other conditions that, in the judgment of the investigator, make inclusion in the study inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate;AE; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor treatment-related neutropenia;Tumor treatment-related thrombocytopenia;Tumor treatment-related anemia; | — |
Countries
China
Contacts
Public ContactHu Ma
The Second Affiliated Hospital of Zunyi Medical University
Outcome results
None listed